Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

New Data Highlight Effectiveness of Guselkumab for Patients with PsA

Michele B. Kaufman, PharmD, BCGP  |  February 2, 2022

The use of guselkumab improved joint and skin symptoms in biologic naive patients with PsA, according to research presented during ACR Convergence 2021.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2021guselkumabPsAPsoriatic Arthritis

Tigulixostat Appears Promising for the Treatment of Gout

Michele B. Kaufman, PharmD, BCGP  |  February 2, 2022

In a phase 2 study, tigulixostat treatment proved safe for lowering serum uric acid (sUA) levels in patients with gout.

Filed under:ACR ConvergenceConditionsDrug UpdatesGout and Crystalline ArthritisMeeting Reports Tagged with:ACR Convergence – GoutACR Convergence 2021ACR Convergence 2021 – GoutGoutserum uric acidtigulixostat

FDA Approves Secukinumab for Children with Enthesitis-Related Arthritis & PsA

Michele B. Kaufman, PharmD, BCGP  |  February 2, 2022

The FDA has approved the use of secukinumab for pediatric patients with enthesitis-related arthritis and psoriatic arthritis, after research showed a longer time to disease flare than placebo.

Filed under:ConditionsDrug UpdatesPediatric Conditions Tagged with:enthesitis-related arthritis (ERA)FDAFDA approvalPediatricPediatric RheumatologyPsAPsoriatic ArthritissecukinumabU.S. Food and Drug Administration (FDA)

The Ins & Outs of ILD: The Management & Treatment of ILD in Patients with Rheumatic Disease

Lara C. Pullen, PhD  |  February 2, 2022

Melissa Griffith, MD, discussed the diagnosis and treatment of interstitial lung disease (ILD) in patients with rheumatic diseases, including connective tissue disease and more.

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2021connective tissue diseaseILDinterstitial lung disease (ILD)pneumoniaRheumatoid Arthritis (RA)Sclerodermascleroderma-associated ILD

ACR Town Hall Provides Update on Oral Antiviral Therapy for COVID-19

Katie Robinson  |  January 24, 2022

At an ACR COVID-19 town hall on COVID-19, infectious disease experts discussed the most up-to-datecurrent information on pre- and post-exposure monoclonal antibody therapy, oral antivirals and vaccines for rheumatology patients.

Filed under:Conditions Tagged with:COVID-19immunosuppressive drugsmonoclonal antibodyvaccine

Key 2022 Coding & Billing Updates

From the College  |  January 23, 2022

In 2022, rheumatology practices should prepare for documentation, coding, billing and reimbursement revisions related to evaluation and management (E/M), split/shared billing policies and telehealth services.

Filed under:Billing/Coding Tagged with:Billing & CodingE/M Codingtelehealth

ACR Insurance Subcommittee Chair Encourages Member Engagement

Carina Stanton  |  January 20, 2022

Rheumatology practices have a voice in payer advocacy through the Insurance Subcommittee of the ACR’s Committee on Rheumatologic Care.

Filed under:InsuranceLegislation & AdvocacyProfiles Tagged with:ACR Insurance Subcommittee (ISC)AdvocacyCommittee on Rheumatologic Care (CORC)insurance advocacyRebecca Shepherd

Insights into JAK Inhibitor Use

Michele B. Kaufman, PharmD, BCGP  |  January 20, 2022

According to a German study presented during ACR Convergence 2021, treatment persistence with JAK inhibitors is comparable to TNF inhibitors and other bDMARDs among patients with rheumatoid arthritis.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2021ACR Convergence 2021 – RAJAK inhibitorsRheumatoid Arthritis (RA)

Defining Administration Complexity by the Drug, Not the Diagnosis

Mary Beth Nierengarten  |  January 10, 2022

Enabling rheumatology practices to use complex administration codes for biologic drugs is critical for maintaining patient access to essential therapies.

Filed under:Billing/CodingBiologics/DMARDsLegislation & Advocacy Tagged with:BiologicsCodingCommittee on Rheumatologic Care (CORC)Local Coverage Article (LCA)Local Coverage Determination (LCD)Medicare Administrative Contractors (MACs)

Harder to Breathe: The Infrastructure Behind Medical Oxygen

Philip Seo, MD, MHS  |  January 10, 2022

Last year, in Texas, they had no room to breathe. Texas has 301 designated trauma centers equipped to provide intensive care, 200 of which can care for at least four critically ill patients. In August 2021, 75 of these hospitals reported having no available beds in their intensive care units. Zero. This was due, in…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:infrastructure

  • « Previous Page
  • 1
  • …
  • 54
  • 55
  • 56
  • 57
  • 58
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences